Erkurt Mehmet Ali, Sarici Ahmet, Berber İlhami, Kuku İrfan, Kaya Emin, Özgül Mustafa
Inonu University, Turgut Ozal Medical Center, Adult Hematology Department, Malatya, Turkey.
Transfus Apher Sci. 2020 Oct;59(5):102867. doi: 10.1016/j.transci.2020.102867. Epub 2020 Jun 27.
Convalescent Plasma (CP) therapy is of interest as no vaccine or specific treatment is available for emerging viruses such as severe acute respiratory syndrome coronavirus 2 causing Covid-19. It was aimed to report the results of our patients who underwent CP in the treatment of Covid-19.
CP treatment was applied to 26 Covid-19 patients in intensive care unit who had quantitative reverse transcriptase-polymerase chain reaction positive Sars-Cov-2 infection. Plasma was collected at least 14 days after complete recovery from patients who had mild or moderate infection with Sars-Cov-2 infection. The collected CP (200cc) were applied to severe Covid-19 patients. Laboratory values of patients just before CP and after 7 days were compared.
There were no statistically significant differences in leukocyte, neutrophil, lymphocyte, platelet, CRP, ferritin, LDH, ALT, AST, sO and total bilirubin values just before and after 1 week of CP. A statistically significant difference was found between age and lymphocyte values of living and dying patients. The patients who died were determined to have older age (74,6 vs 61,85, p = 0,018) and more severe lymphopenia (0,47 vs 1,18, p = 0,001).
CP therapy has the potential to provide immediate and promising treatment options before specific vaccines and treatments are developed. In early stage Covid-19 patients who do not need mechanical ventilation, CP treatment may be a curative treatment option.
由于对于诸如导致新冠肺炎的严重急性呼吸综合征冠状病毒2等新兴病毒，尚无疫苗或特效治疗方法，恢复期血浆（CP）疗法备受关注。本研究旨在报告接受CP治疗的新冠肺炎患者的治疗结果。
对26例在重症监护病房、严重急性呼吸综合征冠状病毒2（Sars-Cov-2）定量逆转录聚合酶链反应检测呈阳性的新冠肺炎患者进行CP治疗。从轻度或中度感染Sars-Cov-2且已完全康复至少14天的患者中采集血浆。将采集的CP（200cc）应用于重症新冠肺炎患者。比较患者在接受CP治疗前及治疗7天后的实验室检查值。
接受CP治疗1周前后，患者的白细胞、中性粒细胞、淋巴细胞、血小板、CRP、铁蛋白、乳酸脱氢酶、谷丙转氨酶、谷草转氨酶、血氧饱和度及总胆红素值无统计学显著差异。存活患者与死亡患者的年龄及淋巴细胞值存在统计学显著差异。死亡患者年龄更大（74.6岁 vs 61.85岁，p = 0.018），淋巴细胞减少更严重（0.47 vs 1.18，p = 0.001）。
在开发出特定疫苗和治疗方法之前，CP疗法有可能提供即时且有前景的治疗选择。对于早期不需要机械通气的新冠肺炎患者，CP治疗可能是一种有效的治疗选择。
